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A bs tr ac t
Background
Improved diagnostic tests for tuberculosis in children are needed. We hypothesized 
that transcriptional signatures of host blood could be used to distinguish tubercu-
losis from other diseases in African children who either were or were not infected 
with the human immunodeficiency virus (HIV).
Methods
The study population comprised prospective cohorts of children who were undergoing 
evaluation for suspected tuberculosis in South Africa (655 children), Malawi (701 chil-
dren), and Kenya (1599 children). Patients were assigned to groups according to whether 
the diagnosis was culture-confirmed tuberculosis, culture-negative tuberculosis, dis-
eases other than tuberculosis, or latent tuberculosis infection. Diagnostic signatures 
distinguishing tuberculosis from other diseases and from latent tuberculosis infec-
tion were identified from genomewide analysis of RNA expression in host blood.
Results
We identified a 51-transcript signature distinguishing tuberculosis from other dis-
eases in the South African and Malawian children (the discovery cohort). In the 
Kenyan children (the validation cohort), a risk score based on the signature for tu-
berculosis and for diseases other than tuberculosis showed a sensitivity of 82.9% 
(95% confidence interval [CI], 68.6 to 94.3) and a specificity of 83.6% (95% CI, 74.6 
to 92.7) for the diagnosis of culture-confirmed tuberculosis. Among patients with 
cultures negative for Mycobacterium tuberculosis who were treated for tuberculosis 
(those with highly probable, probable, or possible cases of tuberculosis), the esti-
mated sensitivity was 62.5 to 82.3%, 42.1 to 80.8%, and 35.3 to 79.6%, respectively, 
for different estimates of actual tuberculosis in the groups. In comparison, the sen-
sitivity of the Xpert MTB/RIF assay for molecular detection of M. tuberculosis DNA in 
cases of culture-confirmed tuberculosis was 54.3% (95% CI, 37.1 to 68.6), and the 
sensitivity in highly probable, probable, or possible cases was an estimated 25.0 to 
35.7%, 5.3 to 13.3%, and 0%, respectively; the specificity of the assay was 100%.
Conclusions
RNA expression signatures provided data that helped distinguish tuberculosis from 
other diseases in African children with and those without HIV infection. (Funded by 
the European Union Action for Diseases of Poverty Program and others).
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Between 500,000 and 1 million new cases of childhood tuberculosis are diag-nosed annually, but the true global burden 
of childhood tuberculosis is unknown because 
it is often difficult to confirm the diagnosis 
 microbiologically.1-3 Although most cases of 
 tuberculosis in adults are diagnosed through 
detection of acid-fast bacilli on microscopic ex-
amination of a sputum specimen, in the major-
ity of childhood cases, smears and cultures are 
negative for Mycobacterium tuberculosis, and the 
diagnosis is made solely on clinical grounds.1,3 
Since the symptoms and signs of childhood tu-
berculosis are seen in a range of other condi-
tions, clinical diagnosis is unreliable.4 Clinical 
scoring systems designed to aid diagnosis have 
not been validated against the standard of 
culture- confirmed diagnosis, and the diagnos-
tic accuracy of these systems varies markedly.5-7 
Over diagnosis and thus inappropriate treatment 
of childhood tuberculosis is common.8 Con-
versely, underdiagnosis contributes to a poor out-
come,9 and tuberculosis is often identified only 
when patients are critically ill or at postmortem 
investigations.10
Microbiologic diagnosis of childhood tubercu-
losis usually requires hospital admission to obtain 
gastric-lavage fluids or saline-induced sputum.11 
Even then, microbiologic confirmation is achieved 
in only a small proportion of treated cases be-
cause of the paucibacillary nature of childhood 
tuberculosis and the characteristic extrapulmo-
nary presentation.1-3 Radiographic findings in 
childhood tuberculosis are nonspecific,12 and the 
tuberculin skin test and interferon-γ–release as-
say (IGRA) cannot differentiate active disease 
from latent infection.13 Furthermore, children with 
tuberculosis, particularly those who are infected 
with the human immunodeficiency virus (HIV) or 
are malnourished, may have nonreactive results 
for both the tuberculin skin test and the IGRA.14-17 
Improved methods for diagnosing childhood tu-
berculosis are thus urgently needed, particularly 
in countries of sub-Saharan Africa where the 
burden of tuberculosis and HIV coinfection is 
highest.1,2,18-20 We investigated the use of ge-
nomewide RNA expression in host blood to 
distinguish tuberculosis from other diseases 
that are prevalent among African children with 
and those without HIV infection and explored 
the use of a score for disease risk derived from 
the transcriptional signature as the basis for a 
possible diagnostic test.
Me thods
Study Conduct and Oversight 
We recruited patients between February 17, 2008, 
and January 27, 2011. Clinical data were anony-
mized, and patient samples identified according 
to study number. Assignments to diagnostic groups 
were made independently by two experienced cli-
nicians, and any discrepancies in these assign-
ments were resolved by a third clinician. Statisti-
cal analysis was conducted after the database on 
RNA expression and the clinical database had 
been locked (on February 4, 2011). An analysis 
plan was approved and analysis commenced af-
ter an amendment was made to use the South 
African and Malawi cohorts for discovery of the 
RNA signature and the Kenyan cohort for valida-
tion. This decision was necessitated by the lower-
than-expected recruitment rate for patients with 
culture-confirmed tuberculosis. All the authors 
confirm that the analysis plan was followed and 
accept responsibility for the conduct of the study 
and the accuracy of the data.
The study was approved by the research ethics 
committees of the University of Cape Town, South 
Africa; the University of Malawi, College of Medi-
cine; the Liverpool School of Tropical Medicine; 
Imperial College London; and the Kenya Medi-
cal Research Institute. Trained health workers 
obtained written or oral informed consent from 
the patients’ parents or guardians in their ver-
nacular language. Neither the authors nor the 
sponsors have commercial interests in the out-
comes. Patent applications for the pediatric RNA 
signatures have been submitted on behalf of the 
partner institutions, with the aim of the future 
development of a test for childhood tuberculosis 
in Africa on a nonprofit basis.
Study design 
We recruited children from three African coun-
tries with a high burden of tuberculosis. To 
identify RNA-transcript signatures associated 
with active tuberculosis, we used a discovery 
 cohort comprising children evaluated for sus-
pected tuberculosis in hospitals in South Africa 
and Malawi. We then assessed the performance 
of these signatures in an independent validation 
cohort of children evaluated for suspected tu-
berculosis in hospitals in Kenya. The overall study 
design is shown in Figure 1. Further details on 
the study design and study sites are provided in 
the protocol and in the Methods section and Fig-
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ure S1 in the Supplementary Appendix; the proto-
col and the Supplementary Appendix are available 
with the full text of this article at NEJM.org. 
Gene-expression data are available at the Nation-
al Center for Biotechnology Information Gene 
Expression Omnibus (GEO) and can be accessed 
through GEO Series accession number GSE39941 
at www.ncbi.nlm.nih.gov/geo.
Diagnostic Process
A systematic diagnostic evaluation was per-
formed in children younger than 15 years of age 
who had a cough, fever, or weight loss of more 
than 2 weeks’ duration; pneumonia that was un-
responsive to antibiotics; any other clinical find-
ings that were suggestive of tuberculosis; or a 
history of close contact with an adult who had 
tuberculosis (Fig. 2). The investigation included 
chest radiography, measurement of the C-reactive 
protein level, a serologic test or polymerase-
chain-reaction (PCR) assay for HIV, and a tuber-
culin skin test, with or without an IGRA. Two 
spontaneous or induced sputum samples and 
a specimen of tissue or cerebrospinal fluid (if 
clinically indicated) were examined for acid-fast 
bacilli and cultured for mycobacteria. The Xpert 
MTB/RIF21 real-time PCR assay (a test for M. tuber-
culosis and resistance to rifampin) was performed 
on respiratory samples in the Kenyan cohort. 
Bacterial cultures, histologic examination of tis-
sue-biopsy specimens, and analysis of blood 
films for the presence of malaria were performed 
as clinically indicated. Clinical follow-up was un-
dertaken at 3 months to confirm that children 
with latent tuberculosis infection remained free 
of active tuberculosis and other diseases and to 
determine whether there had been a response to 
treatment in children with confirmed or suspected 
tuberculosis.
Case Definitions
Culture-confirmed tuberculosis was defined as the 
isolation of M. tuberculosis from a child with clini-
cal features of tuberculosis, and culture-negative 
tuberculosis was defined as a negative mycobac-
terial culture in a child with clinical and radio-
logic features that prompted empirical treatment 
for tuberculosis. Culture-negative tuberculosis 
was further categorized as a case in which tuber-
culosis was highly probable, probable, or possible 
on the basis of a priori study definitions (Fig. 2). 
Children were classified as having latent tuber-
culosis infection if they had contact with a person 
who had a positive smear for tuberculosis, were 
healthy on presentation and follow-up, and had 
positive results on both the tuberculin skin test 
and the IGRA if in the discovery cohort and had 
positive results on either the tuberculin skin test 
or the IGRA if in the validation cohort. Children 
were classified as having diseases other than tu-
berculosis if they received a definitive alternative 
diagnosis or had no clinical deterioration on 
follow-up in the absence of tuberculosis therapy 
(Fig. 2). Since a positive result on an IGRA in the 
group of patients with diseases other than tuber-
culosis might indicate either latent tuberculosis 
infection or primary tuberculosis that had re-
solved without treatment, we excluded patients 
in the discovery cohort who had a positive result 
on an IGRA. In the Kenyan validation cohort, pa-
tients who had diseases other than tuberculosis 
were included in the study regardless of whether 
an IGRA result was positive or negative.
Microarray Analysis of Blood RNA Expression
Whole blood was collected in PAXgene Blood 
RNA Tubes (PreAnalytiX) at the time of study re-
cruitment, frozen within 6 hours after collection, 
and later extracted with the use of PAXgene Blood 
RNA Kits. RNA was shipped to the Genome In-
stitute of Singapore for analysis on HumanHT-12 
v.4 Expression BeadChip arrays (Illumina). Infor-
mation on microarray methods, quality control, 
and analysis is provided in the Methods section 
and Figure S2 in the Supplementary Appendix.
Statistical Analysis
Gene-expression data were analyzed with the use 
of R: A Language and Environment for Statistical 
Computing (R Foundation for Statistical Com-
puting). Patients in the discovery cohort were as-
signed to training and test sets (80% and 20% of 
the cohort, respectively). We used the training set 
to identify transcripts that were differentially ex-
pressed between tuberculosis and other diseases 
and also between active tuberculosis and latent 
infection, irrespective of HIV status or geographic 
location; differential expression was defined as 
an absolute log2 intensity ratio of more than 0.5. 
To identify the smallest number of transcripts 
distinguishing tuberculosis from the comparator 
groups, we subjected these transcripts to variable 
selection using elastic net22 (see the Methods sec-
tion in the Supplementary Appendix).
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Array-based technologies are not appropriate 
for use in resource-poor regions because of 
their cost and the complex technology required. 
We therefore developed a method for translating 
multitranscript RNA signatures into a single score 
for disease risk that could form the basis of a 
Clinical assessment, chest radiography, TST, HIV test, IGRA, induced sputum for tuberculosis culture
(other investigations as clinically indicated — e.g., lumbar puncture, fine-needle aspiration, pleural or ascitic tap)
Inclusion criteria (any of the following):
Cough, fever, or weight loss for >2 wk
Pneumonia not responding to antibiotics
History of close tuberculosis contact
Clinician’s clinical suspicion of tuberculosis for any other reason
Well child identified through
contact tracing
Treatment for other diseases
2 Negative sputum cultures
Definite alternative diagnosis
Well at follow-up without
 tuberculosis treatment
No clinical features of tuberculosis 
No radiographic features of 
    tuberculosis 
Positive IGRA, positive TST, or 
    both
M. tuberculosis not isolated from
clinical specimens 
(induced sputum, gastric 
washings, CSF, tissue or fluid
from normally sterile site)
Treatment for tuberculosis as
clinically indicated
M. tuberculosis isolated from ≥1 
clinical specimens 
(induced sputum, gastric 
washings, CSF, tissue or fluid 
from normally sterile site)
Culture-Negative TuberculosisConfirmed Tuberculosis
Highly Probable Tuberculosis Probable Tuberculosis Possible Tuberculosis
Other Diagnosis
(tuberculosis excluded)
Latent Tuberculosis
Symptoms of tuberculosis >2 wk
and reactive TST or positive 
acid-fast bacilli smear
and 1 of the following:
Radiographic findings
Abdominal features
CSF features with or without 
CT-scan findings
Spinal features (gibbus) with or
without radiological findings 
Tuberculosis lymphadenitis
Histologic features at site
of infection
Symptoms of tuberculosis >2 wk
and 1 of the following:
Reactive TST
Acid-fast bacilli on microscopy
Radiographic findings
Abdominal features
CSF features with or without 
CT-scan findings
Tuberculosis lymphadenitis
Histologic features at site
of infection
Good response to 
    tuberculosis treatment
Symptoms of tuberculosis >2 wk
and 1 of the following:
Household contact
No alternative diagnosis 
established
Figure 2. Diagnostic Algorithm.
With regard to the inclusion criteria, patients with failure to thrive for more than 4 weeks were included in the Kenyan cohort. In the group 
receiving treatment for other diseases, patients with IGRA-positive results were excluded from the South Africa and Malawi cohorts but in-
cluded in the Kenyan cohort. In the culture-negative group, the IGRA was repeated for patients in whom tuberculosis was suspected and 
the initial IGRA was negative; findings on radiography included effusion, extensive consolidation, cavitation, lymphadenopathy, miliary 
disease, and lobar pneumonia that was not responding to antibiotics, and abdominal features included ascites and lymphadenopathy. 
CSF denotes cerebrospinal fluid, CT computed tomography, IGRA interferon-γ–release assay, and TST tuberculin skin test.
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simple diagnostic test. Transcripts from the 
minimal signatures were classified as up-regulated 
or down-regulated on the basis of their expression 
relative to each comparator group in the training 
data set. The risk score for disease was derived 
by adding the total intensity of the up-regulated 
transcripts and subtracting the total intensity 
of the down-regulated transcripts (see Equa-
tion 1 in the Methods section in the Supple-
mentary Appendix). For each patient, we calcu-
lated the risk score using the minimal transcript 
sets for tuberculosis as compared with other 
diseases and as compared with latent tubercu-
losis infection.
In the Kenyan validation cohort, we com-
pared the performance of the disease risk score 
with that of Xpert MTB/RIF assay within each of 
four groups: the group with culture-confirmed 
tuberculosis and the culture-negative groups with 
highly probable, probable, or possible tubercu-
losis. In each evaluation, the same tuberculosis-
negative comparator group (i.e., children with 
diseases other than tuberculosis) was used to 
calculate test specificity (Table 1). We used a 
range of estimates of the true rate of positive 
test results for tuberculosis in the groups with 
highly probable, probable, or possible tuberculo-
sis in order to model the performance of the risk 
score and the Xpert MTB/RIF assay and to pro-
vide an estimate of the sensitivity of each test 
(effective sensitivity) (see the Methods section 
in the Supplementary Appendix).
R esult s
Discovery Cohort
After screening and evaluating 1356 children in 
South Africa and Malawi for symptoms of tuber-
culosis, we included 157 patients from South Af-
rica and 189 patients from Malawi in the RNA 
expression studies. Of these 346 children, 114 had 
culture-confirmed tuberculosis, 175 had diseases 
other than tuberculosis, and 57 had latent tuber-
culosis infection. The discovery cohort included 
only those children with tuberculosis that was 
confirmed on culture; children for whom the di-
agnosis of tuberculosis could not be confidently 
established or ruled out were excluded. (Details 
of recruitment are provided in Fig. S1A and S1B 
and clinical details in Table S1A and S1B in the 
Supplementary Appendix.)
Identification of Tuberculosis Signature
In the training set (comprising 80% of samples 
from the discovery cohort), we identified 409 tran-
scripts that were differentially expressed between 
tuberculosis and other diseases and 3434 tran-
scripts that were differentially expressed between 
tuberculosis and latent infection. Using variable 
selection to identify the smallest number of tran-
scripts that distinguished each group, we found 
that 51 transcripts distinguished tuberculosis 
from other diseases and 42 distinguished tuber-
culosis from latent infection (Table S2A and S2B 
in the Supplementary Appendix). These minimal 
transcript sets were used to generate a risk score 
for each patient in the test set (comprising the 
remaining 20% of samples from the discovery 
cohort) that distinguished tuberculosis from other 
diseases (sensitivity of 78% and specificity of 
74%) and that distinguished tuberculosis from 
latent infection (sensitivity of 96% and specificity 
of 91%) (Table 2, and Table S3 and Fig. S3 and S4 
in the Supplementary Appendix).
Assessment of Risk Score in Validation Cohort
A total of 1599 children presenting to hospitals 
in Kenya met the inclusion criteria for the study, 
and 1471 were evaluated for tuberculosis.23 We 
included 157 of these children in a nested case–
control study that included the group with culture-
confirmed tuberculosis and all subgroups in the 
group with culture-negative tuberculosis (i.e., those 
in whom tuberculosis was highly probable, prob-
able, or possible). We included all patients with 
culture-confirmed tuberculosis or latent infec-
tion for whom we had adequate RNA samples 
(35 and 14 patients, respectively), 44 patients with 
culture-negative tuberculosis (8 patients in whom 
tuberculosis was highly probable, 19 in whom it 
was probable, and 17 in whom it was possible) 
(Table S4 in the Supplementary Appendix), and 
64 randomly selected patients from the group 
with diseases other than tuberculosis (55 with 
negative IGRA results and 9 with positive IGRA 
results). Clinical features of the patients included 
in the microarray study, which are summarized 
in Table 1, were similar to the clinical features of 
patients who were not included, with two excep-
tions: in the group with probable tuberculosis, a 
history of close contact with a person who had 
tuberculosis was more common among patients 
included in the microarray study (Table S5A in 
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on May 27, 2019. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 370;18 nejm.org may 1, 20141718
Ta
bl
e 
1.
 C
lin
ic
al
 C
ha
ra
ct
er
is
tic
s 
of
 C
hi
ld
re
n 
in
 th
e 
K
en
ya
n 
V
al
id
at
io
n 
C
oh
or
t.*
C
ha
ra
ct
er
is
tic
C
ul
tu
re
-C
on
fir
m
ed
 T
B,
 
H
IV
-N
eg
at
iv
e 
 
(N
 =
 2
5)
C
ul
tu
re
-C
on
fir
m
ed
 T
B,
 
H
IV
-P
os
iti
ve
  
(N
 =
 1
0)
†
C
ul
tu
re
-N
eg
at
iv
e 
TB
, 
H
IV
-N
eg
at
iv
e 
 
(N
 =
 2
7)
C
ul
tu
re
-N
eg
at
iv
e 
TB
, 
H
IV
-P
os
iti
ve
  
(N
 =
 1
7)
†
La
te
nt
 I
nf
ec
tio
n,
  
H
IV
-N
eg
at
iv
e 
 
(N
 =
 1
4)
O
th
er
 D
is
ea
se
s,
  
H
IV
-N
eg
at
iv
e 
 
(N
 =
 3
7)
O
th
er
 D
is
ea
se
s,
 
H
IV
-P
os
iti
ve
 
(N
 =
 2
7)
†
A
ge
 —
 m
o
M
ed
ia
n
37
10
1
22
32
33
20
38
In
te
rq
ua
rt
ile
 r
an
ge
12
 to
 1
06
53
 to
 1
27
12
 to
 4
0
18
 to
 6
0
18
 to
 4
3
11
 to
 8
9
16
 to
 7
8
M
al
e 
se
x 
—
 n
o.
 (
%
)
13
 (
52
)
6 
(6
0)
15
 (
56
)
10
 (
59
)
7 
(5
0)
24
 (
65
)
19
 (
70
)
W
ei
gh
t-
fo
r-
ag
e 
z 
sc
or
e‡
M
ed
ia
n
−2
.4
−3
.6
−2
.5
−3
.5
−1
.6
−2
.7
−3
.3
In
te
rq
ua
rt
ile
 r
an
ge
−3
.4
 to
 −
1.
0
−4
.3
 to
 −
2.
7
−3
.6
 to
 −
1.
6
−4
.5
 to
 −
3.
0
−2
.1
 to
 −
1.
2
−3
.8
 to
 −
2.
2
−4
.4
 to
 −
1.
7
B
C
G
 v
ac
ci
na
tio
n 
—
 n
o.
 (
%
)
24
 (
96
)
9 
(9
0)
23
 (
85
)
16
 (
94
)
11
 (
79
)
33
 (
89
)
23
/2
6 
(8
8)
H
is
to
ry
 o
f c
lo
se
 T
B
 c
on
ta
ct
 —
  
no
. (
%
)
14
 (
56
)
8 
(8
0)
14
 (
52
)
7 
(4
1)
14
 (
10
0)
2 
(5
)
4 
(1
5)
Po
si
tiv
e 
tu
be
rc
ul
in
 s
ki
n 
te
st
 —
 
no
. (
%
)§
17
 (
68
)
3 
(3
0)
13
 (
48
)
2 
(1
2)
14
 (
10
0)
1 
(3
)
3 
(1
1)
Po
si
tiv
e 
IG
RA
 —
 n
o/
to
ta
l n
o.
 (%
)¶
7/
10
 (
70
)
2/
5 
(4
0)
9/
14
 (
64
)
3/
10
 (
30
)
14
 (
10
0)
8/
32
 (
25
)
1/
22
 (
5)
C
ou
gh
 fo
r 
>2
 w
k 
—
 n
o.
 (
%
)
15
 (
60
)
8 
(8
0)
14
 (
52
)
14
 (
82
)
0
10
 (
27
)
13
 (
48
)
Fe
ve
r 
fo
r 
>2
 w
k 
—
 n
o.
 (
%
)
15
 (
60
)
7 
(7
0)
9 
(3
3)
9 
(5
3)
0
11
 (
30
)
10
 (
37
)
N
ig
ht
 s
w
ea
ts
 fo
r 
>2
 w
k 
—
  
no
. (
%
)
9 
(3
6)
6 
(6
0)
10
 (
37
)
2 
(1
2)
0
4 
(1
1)
6 
(2
2)
W
ei
gh
t l
os
s 
or
 fa
ilu
re
 to
 th
ri
ve
 —
 
no
. (
%
)
16
 (
64
)
9 
(9
0)
18
 (
67
)
13
 (
76
)
1 
(7
)
30
 (
81
)
20
 (
74
)
R
ad
io
gr
ap
hi
c 
fe
at
ur
es
 o
f T
B
 —
 
no
. (
%
)
19
 (
76
)
9 
(9
0)
17
 (
63
)
12
 (
71
)
0
10
 (
27
)
11
 (
41
)
C
ul
tu
re
-p
os
iti
ve
 T
B
 —
 n
o.
 (
%
)
25
 (
10
0)
‖
10
 (
10
0)
‖
0
0
0
0
0
* 
B
C
G
 d
en
ot
es
 b
ac
ill
e 
C
al
m
et
te
–G
ué
ri
n,
 H
IV
 h
um
an
 im
m
un
od
ef
ic
ie
nc
y 
vi
ru
s,
 I
G
R
A
 in
te
rf
er
on
-γ
–r
el
ea
se
 a
ss
ay
, a
nd
 T
B
 t
ub
er
cu
lo
si
s.
 W
he
re
 d
at
a 
on
 a
 p
ar
tic
ul
ar
 fe
at
ur
e 
w
er
e 
no
t 
av
ai
la
bl
e 
fo
r 
al
l p
at
ie
nt
s 
in
 a
 g
ro
up
, t
he
 d
en
om
in
at
or
 fo
r 
w
hi
ch
 d
at
a 
w
er
e 
av
ai
la
bl
e 
is
 in
di
ca
te
d.
†
 A
m
on
g 
th
e 
ch
ild
re
n 
w
ho
 w
er
e 
H
IV
-p
os
iti
ve
, 1
6 
w
er
e 
re
ce
iv
in
g 
an
tir
et
ro
vi
ra
l t
he
ra
py
.
‡
 T
he
 w
ei
gh
t-
fo
r-
ag
e 
z 
sc
or
e 
is
 b
as
ed
 o
n 
th
e 
nu
m
be
r 
of
 s
ta
nd
ar
d 
de
vi
at
io
ns
 o
f t
he
 a
ct
ua
l w
ei
gh
t 
of
 a
 c
hi
ld
 fr
om
 t
he
 m
ed
ia
n 
w
ei
gh
t 
of
 c
hi
ld
re
n 
of
 t
he
 s
am
e 
ag
e 
an
d 
se
x.
 T
he
 w
ei
gh
t-
fo
r-
ag
e 
st
an
da
rd
s 
w
er
e 
de
ri
ve
d 
w
ith
 t
he
 u
se
 o
f t
he
 N
at
io
na
l C
en
te
r 
fo
r 
H
ea
lth
 S
ta
tis
tic
s–
W
or
ld
 H
ea
lth
 O
rg
an
iz
at
io
n 
in
te
rn
at
io
na
l r
ef
er
en
ce
 p
op
ul
at
io
n.
§ 
A
 p
os
iti
ve
 r
es
ul
t 
on
 t
he
 t
ub
er
cu
lin
 s
ki
n 
te
st
 w
as
 d
ef
in
ed
 a
cc
or
di
ng
 t
o 
gu
id
el
in
es
 fr
om
 t
he
 W
or
ld
 H
ea
lth
 O
rg
an
iz
at
io
n 
as
 a
n 
in
du
ra
tio
n 
of
 1
0 
m
m
 o
r 
m
or
e 
in
 c
hi
ld
re
n 
w
ith
ou
t 
H
IV
 in
fe
ct
io
n 
or
 s
ev
er
e 
m
al
nu
tr
iti
on
 a
nd
 a
s 
5 
m
m
 o
r 
m
or
e 
in
 c
hi
ld
re
n 
w
ith
 H
IV
 in
fe
ct
io
n 
or
 s
ev
er
e 
m
al
nu
tr
iti
on
.
¶
 T
he
 t
ot
al
 n
um
be
r 
is
 t
he
 n
um
be
r 
of
 c
hi
ld
re
n 
w
ho
 w
er
e 
te
st
ed
 fo
r 
w
ho
m
 v
al
id
 r
es
ul
ts
 w
er
e 
av
ai
la
bl
e.
 
‖ 
A
m
on
g 
th
e 
ch
ild
re
n 
w
ho
 h
ad
 a
 p
os
iti
ve
 c
ul
tu
re
 fo
r 
TB
, s
ix
 a
ls
o 
ha
d 
po
si
tiv
e 
re
su
lts
 o
n 
sm
ea
rs
 fo
r 
ac
id
-fa
st
 b
ac
ill
i.
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on May 27, 2019. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
Childhood Tuberculosis and Host RNA Expression
n engl j med 370;18 nejm.org may 1, 2014 1719
the Supplementary Appendix), and in the group 
with diseases other than tuberculosis, weight 
loss and pleural effusion were more common 
among patients who were included (Table S5B in 
the Supplementary Appendix).
The risk score discriminated culture-confirmed 
tuberculosis from other diseases in patients with 
or without HIV infection with a sensitivity of 82.9% 
and a specificity of 83.6% when patients with 
other diseases who had a positive IGRA result 
were excluded. When patients in the group with 
diseases other than tuberculosis who had a 
positive IGRA result were included, the specific-
ity and sensitivity of the risk score were not af-
fected (Table 2 and Fig. 3, and Table S6 and Fig. 
S5 in the Supplementary Appendix). The major-
ity of patients in the group with diseases other 
than tuberculosis who had a positive IGRA result 
were classified as not having tuberculosis (7 of 
9 patients) (see the Methods section and Fig. S3 
in the Supplementary Appendix). Among patients 
with negative cultures who were treated for tu-
berculosis, the risk score identified 62.5% of 
those in whom tuberculosis was highly proba-
ble, 42.1% of those in whom it was probable, and 
35.3% of those in whom it was possible. Since it 
was not known what proportion of patients had 
actual tuberculosis (as opposed to patients who 
were treated on the basis of suspicion of dis-
ease), we adjusted for the estimated prevalence 
of actual tuberculosis in each of these subgroups 
to calculate an effective sensitivity (see the Meth-
ods section in the Supplementary Appendix); 
the effective sensitivity of the risk score for 
highly probable, probable, and pos sible cases of 
tuberculosis was 67.6 to 82.3%, 59.3 to 80.8%, 
and 54.3 to 79.6%, respectively (Table S7 in 
the Supplementary Appendix). The sensitivity of 
the risk score was higher than that of the Xpert 
MTB/RIF assay in all tuberculosis categories, 
with the Xpert MTB/RIF assay having sensitivi-
ties of 27.8 to 35.7% for the subgroup in which 
tuberculosis was highly probable, 8.8 to 13.3% 
for that in which it was probable, and 0% for 
that in which it was possible (Fig. 3, and Table 
S7 in the Supplementary Appendix). However, 
the Xpert MTB/RIF assay was highly specific 
(100%). The risk score also distinguished tuber-
culosis from latent infection, with a sensitivity 
of 94% and a specificity of 100% (Table S3 and 
Fig. S4 in the Supplementary Appendix). Finally, 
we compared the diagnostic performance of the 
risk score with that of the IGRA and measure-
ment of the C-reactive protein level (which has 
been reported as a biomarker of tuberculosis24). 
The C-reactive protein level proved to be of no 
Table 2. Diagnostic Performance of the Risk Score in the Discovery and Validation Cohorts and as Compared with the IGRA and the Xpert 
MTB/RIF Assay in the Validation Cohort.*
Performance Measure Risk Score IGRA
Xpert MTB/RIF 
Assay†
Test Set in the 
Discovery Cohort
Validation Cohort, 
Excluding Children 
with Positive IGRA  
in Group with  
Other Diseases
Validation Cohort, 
Including Children 
with Positive IGRA  
in Group with  
Other Diseases Validation Cohort Validation Cohort
No. of patients with TB 23 35 35 35 35
No. of patients with other 
diseases
34 55 64 54 55
Area under ROC curve 
(95% CI)
86.2 (77.1–94.0) 89.0 (82.3–94.9) 89.0 (81.9–95.3) 71.7 (58.3–84.8) 77.1 (69.9–85.7)
Sensitivity — % (95% CI) 78.3 (60.9–95.7) 82.9 (68.6–94.3) 82.9 (68.6–94.3) 60.0 (33.3–86.67) 54.3 (37.1–68.6)
Specificity — % (95% CI) 73.5 (55.9–88.2) 83.6 (74.6–92.7) 82.8 (73.4–92.2) 83.3 (72.2–92.6) 100.0 (100.0–100.0)
* Patients in the discovery cohort of South African and Malawian children were assigned to training and test sets (80% and 20% of the co-
hort, respectively). The 51-transcript signature used in the group with diseases other than TB was derived from data on the South African 
and Malawian patients in the training set and applied to the independent Kenyan validation cohort. All analyses included children with and 
those without HIV infection. Sensitivity and specificity were calculated with the use of a weighted threshold for classification. ROC denotes 
receiver-operating-characteristic. CI denotes confidence interval.
† The Xpert MTB/RIF assay was positive for 19 of 35 patients with culture-confirmed tuberculosis and none of 55 patients with diseases other 
than tuberculosis.
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value in discriminating childhood tuberculosis 
from other diseases (Fig. S6 in the Supplementary 
Appendix), and for this purpose, the risk score 
was significantly more sensitive than the IGRA 
(82.9% vs. 60.0%) (Table 2).
To explore the ways in which the risk score 
might contribute to the diagnosis of tuberculo-
sis in clinical practice, we evaluated its positive 
and negative predictive value assuming differ-
ent prevalences of tuberculosis, as follows: 10% 
(the prevalence in the validation cohort), 30% (the 
prevalence in the discovery cohort), and 50% 
(the prevalence that might be expected in a non-
research setting with greater pretest filtering 
according to clinical findings). We also included 
a range of estimates of actual tuberculosis in the 
study group with culture-negative results (for more 
information, see the Methods section in the Sup-
plementary Appendix). The negative predictive 
value was consistently high in all these analy-
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Figure 3. Risk Scores and Sensitivity and Specificity in the Kenyan Validation Cohort, According to Diagnostic Group.
Panel A shows the risk scores for tuberculosis according to study group, calculated with the use of a 51-transcript 
signature applied to the independent Kenyan validation cohort, in which culture-positive tuberculosis was reported 
in 35 patients, diseases other than tuberculosis were reported in 55 patients, and culture-negative tuberculosis was 
reported as highly probable in 5 patients, probable in 19 patients, and possible in 17 patients. The bar within each 
box indicates the median score, the bottom and top of the box indicate the interquartile range, the bars below and 
above the box are at a distance of 0.8 times the interquartile range from the upper and lower edges of the box, and 
the circles indicate outliers; the horizontal line across the graph indicates the mean score. Panel B shows smoothed 
receiver- operating-characteristic (ROC) curves for the sensitivity and specificity of the risk score (solid lines) and 
the Xpert MTB/RIF assay (dotted lines). Panel C shows ROC curves based on an adjusted analysis in which the ac-
tual prevalence of disease was assumed to be 80% among patients in whom the disease was highly probable, 50% 
among those in whom it was probable, and 40% among those in whom it was possible. Sensitivity and specificity 
are reported in Table S7 in the Supplementary Appendix.
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ses. As expected, the positive predictive value 
was higher when more targeted clinical criteria 
were used to select patients for testing (Table S8 
in the Supplementary Appendix).
Discussion
We identified a tuberculosis-specific transcrip-
tome signature in host blood that appears to be 
valuable in distinguishing tuberculosis from other 
diseases with similar clinical features in HIV-
positive and HIV-negative African children. This 
prospective study involved the identification of tu-
berculosis signatures in cohorts from two coun-
tries and validation in an independent cohort in 
a third country. Our findings extend the results 
of previous studies of transcriptome signatures 
in adults and children with tuberculosis.25-33
The major challenge in evaluating new bio-
markers of childhood tuberculosis is the lack 
of a reference standard against which to evalu-
ate them,1,2,20 since microbiologic confirmation 
is achieved in a minority of patients who are 
treated for tuberculosis. It is generally accepted 
that clinical diagnostic scores overdiagnose tu-
berculosis,34 but the extent of overdiagnosis is 
unknown. Conversely, the diagnosis of tubercu-
losis is often overlooked in patients who have 
the disease, and they are often inadvertently 
treated for other diseases.2 To address this chal-
lenge, we first compared the performance of 
our transcriptome signatures and risk score for 
disease with the reference standard of culture-
confirmed tuberculosis; we then assessed the 
performance of the signatures in the culture-
negative group, for which no reference stan-
dard is available. To evaluate biomarkers in 
patients with culture-negative tuberculosis, we 
developed an approach in which estimates of 
the true proportion of patients with tuberculo-
sis in three subgroups (those for whom a diag-
nosis of tuberculosis was considered highly 
probable, probable, or possible) were used to 
calculate an effective sensitivity of the risk 
score. The gradient in the performance of the 
risk score in the culture-negative groups was 
consistent with the different degrees of diag-
nostic certainty in each group. Our findings 
suggest that the risk score provides an im-
proved estimate of the actual prevalence of tu-
berculosis in each diagnostic category and in-
dicate that there is considerable overdiagnosis 
and overtreatment of childhood tuberculosis, 
even in research settings where more sophisti-
cated diagnostic tools are available than in 
most African hospitals.
To define the potential role of our RNA-based 
approach, we compared our risk score for tuber-
culosis with other available diagnostic methods, 
including culture, the Xpert MTB/RIF assay, 
measurement of the C-reactive protein level, and 
the IGRA. Although the Xpert MTB/RIF assay is 
highly specific, our findings confirm the results 
of other studies35 showing that the sensitivity of 
this assay for childhood tuberculosis is limited. 
Our risk score identified higher proportions 
of culture-confirmed cases of tuberculosis and 
culture-negative cases than did the Xpert MTB/RIF 
assay. The risk score was also more sensitive than 
the IGRA; the C-reactive protein level proved to 
be a poor biomarker of childhood tuberculosis.
Use of the disease risk score did result in the 
misclassification of some cases of nontubercu-
lous disease as tuberculosis, which may reflect 
reduced specificity (perhaps resulting from the 
wide variation in the other diseases in the study 
population) or the difficulty of definitively ruling 
out a diagnosis of tuberculosis among children 
in populations in which malnutrition, HIV infec-
tion, other infections, and primary tuberculosis 
are common.1 Conversely, some of the patients 
with culture-negative tuberculosis may in fact 
have had other diseases that were self-limiting. 
In areas where there is a high burden of tuber-
culosis, a considerable proportion of healthy 
children have latent tuberculosis infection and 
have positive IGRA results. Since there was no 
way of establishing whether a child with dis-
eases other than tuberculosis who also had a 
positive IGRA result had primary tuberculosis or 
latent infection, we evaluated our risk score with 
and without the inclusion of children with posi-
tive IGRA results. Our finding that the risk 
score distinguished the majority of children 
with other diseases from children with tuber-
culosis, regardless of IGRA positivity, highlights 
the potential value of the risk score in popula-
tions where latent infection is common.
The translation of transcriptional signatures 
into diagnostic tools in resource-poor communi-
ties is challenging. Innovation will be needed to 
reduce the cost and complexity of the current 
methods used to detect multiple RNA transcripts.
The best application of a blood test based on 
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our risk score and transcriptional signatures in 
clinical practice requires further study. The fact 
that the negative predictive value of the risk score 
is higher than its positive predictive value sug-
gests that the score may be more useful for rul-
ing out tuberculosis than for confirming the di-
agnosis. The development of a test based on this 
risk score for tuberculosis could improve the di-
agnosis and surveillance of childhood tuberculo-
sis in areas with a high or low burden of disease.
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